OnKure Therapeutics
OKUR | NASDAQ
$2.75
+$0.12 (+4.56%)
At close: Nov 16, 2026, 4:00 PM ET
$2.75
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:10 PM ET
OnKure Therapeutics Company Profile
Company profile explainedCompany Profile
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Key Executives
| Name | Position |
|---|---|
| Nicholas A. Saccomano | President, Chief Executive Officer & Director |
| Jason A. Leverone | Chief Financial Officer |
| Dylan Hartley | Chief Scientific Officer |
| Isaac Manke | Senior VP of Business Development & Director |
| James Blake | Senior Vice President of Computational Drug Discovery |
| Kevin S. Litwiler | Senior Vice President of DMPK & Clinical Pharmacology |
| Mark L. Boys | Senior Vice President of Discovery Chemistry |
| Roberta Alton | Senior Vice President of Clinical Operations |
| Rogan Nunn | General Counsel & Secretary |
| Samuel Agresta | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 23, 2026 | 4 | Filing |
| Sep 23, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | 4/A | [Amend] Filing |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 11, 2026 | 4 | Filing |
| Aug 11, 2026 | 4 | Filing |
OnKure Therapeutics
| Country | United States |
| IPO Date | Apr 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Nicholas A. Saccomano |
Contact Details
6707 Winchester Circle Boulder,
Colorado 80301 United States
Stock Details
| Ticker Symbol | OKUR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001637715 |
| CUSIP Number | 68277Q105 |
| ISIN Number | US68277Q1058 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove OKUR